TFA
GPCR icon

Transamerica Financial Advisors’s Structure Therapeutics GPCR Stock Holding History

Transamerica Financial Advisors’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18K Hold
22
– – ﹤0.01% 1448
2026
Q1 		$1.06K Buy
+22
New +$1.51K ﹤0.01% 1326

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Transamerica Financial Advisors's GPCR Position: Q2 2026 in Review

Transamerica Financial Advisors held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 22 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #1448.

Transamerica Financial Advisors first reported a position in GPCR in Q1 2026 and has held it in 2 quarters since. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Transamerica Financial Advisors held 22 shares of Structure Therapeutics worth $1.18K as of Q2 2026.
  • Transamerica Financial Advisors left its Structure Therapeutics share count unchanged in Q2 2026.
  • Structure Therapeutics made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1448 holding.
  • Transamerica Financial Advisors first reported a position in Structure Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.